Extended adjuvant endocrine therapy with an additional 5 years of letrozole after tamoxifen prolonged DFS compared with standard-duration sequential endocrine therapy with letrozole in patients with HR-positive early breast cancer.
Margetuximab + CT resulted in improved PFS and ORR vs trastuzumab + CT in patients with HER2+ MBC after ≥ 2 previous lines of anti-HER2 therapy.
Neratinib + capecitabine significantly prolonged PFS vs lapatinib + capecitabine (HR: 0.76) in patients with HER2+ MBC previously treated with at least 2 lines of therapy.
In patients with advanced PD-L1–positive TNBC, first-line atezolizumab + nab-paclitaxel was associated with a 7 month OS benefit compared with placebo + nab-paclitaxel.
Palbociclib in combination with endocrine therapy and OFS prolonged PFS vs single-agent capecitabine in premenopausal women with HR+/HER2- MBC.
The combination of ribociclib + initial endocrine therapy significantly prolonged median OS vs placebo + endocrine therapy in pre/perimenopausal women with HR+/HER2- advanced breast cancer.